Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today announced that it has signed two exclusive agreements for distribution
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today announced the publication of results showing the cost effectiveness of
Geoffrey Hamilton-Fairley, CEO of Oncimmune, commented: “We are very pleased to announce the commercial availability of our EarlyCDT(R)-Liver test, the second product from our EarlyCDT(R) platform technology, on schedule. Currently
Meinhard Schmidt, Non-Executive Chairman of Oncimmune, commented: “Adam’s direct experience of developing and executing global growth strategies within healthcare will be hugely beneficial to Oncimmune as we continue to expand
Maarten Brusse, Chief Commercial Officer Asia, will be presenting at the GREAT Festival of Innovation taking place from 21-24 March 2018 in Hong Kong. During his presentation, scheduled to take
Geoffrey Hamilton-Fairley, CEO of Oncimmune said of the Interims: “Oncimmune continues to make excellent progress in delivering on the potential of our platform to detect up to four years earlier
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company spun out of the University of Nottingham to develop and commercialise its proprietary EarlyCDT® liquid biopsy platform technology, noted today the
Vaping may raise the risk of certain cancers and heart disease, according to a team of scientists who studied the effects of e-cigarette smoke on healthy mice and human cells.
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) liquid biopsy platform technology, today announces that it has entered into the licence agreement
Oncimmune Holdings plc (LON:ONC), Oncimmune Holdings plc a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) liquid biopsy platform technology, today provides an update on the business
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
